M. Ebisawa

Is a Standard Therapy Against IIIA N2 NSCLC Induction Chemotherapy Plus Surgery

M. Endo, Toshiaki Takahashi, G. Asai, 2002 .

Influence of histological type, smoking history and chemotherapy on survival after first‐line therapy in patients with advanced non‐small cell lung cancer

Yukiko Nakamura, M. Ando, M. Endo, 2007, Cancer science.

Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC).

N. Yamamoto, S. Ueda, G. Asai, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.